MacroGenics Provides Update on Corporate Progress and Third Quarter 2020 Financial Results
November 04, 2020 16:01 ET
|
MacroGenics, Inc.
ROCKVILLE, Md., Nov. 04, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...
MacroGenics Announces Flotetuzumab and Tebotelimab Presentations at the ASH Annual Meeting 2020
November 04, 2020 14:30 ET
|
MacroGenics, Inc.
ROCKVILLE, MD, Nov. 04, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...
MacroGenics Announces Date of Third Quarter 2020 Financial Results Conference Call
October 28, 2020 16:30 ET
|
MacroGenics, Inc.
ROCKVILLE, MD, Oct. 28, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...
MacroGenics Announces Flotetuzumab Publication in Blood Advances
October 15, 2020 16:30 ET
|
MacroGenics, Inc.
ROCKVILLE, MD, Oct. 15, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...
MacroGenics Announces MGC018 Publication in Molecular Cancer Therapeutics
September 23, 2020 07:15 ET
|
MacroGenics, Inc.
Manuscript describes preclinical development of MGC018Phase 1 dose expansion trial evaluating MGC018 in patients with mCRPC, TNBC and NSCLC is currently recruiting patients ROCKVILLE, MD,...
MacroGenics Announces Publication of Flotetuzumab Interim Phase 1/2 Clinical Trial Results in Blood
September 22, 2020 16:30 ET
|
MacroGenics, Inc.
ROCKVILLE, MD, Sept. 22, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...
MacroGenics Announces Development Milestone Achieved in Retifanlimab (MGA012) Collaboration with Incyte
September 21, 2020 07:30 ET
|
MacroGenics, Inc.
$15 Million milestone triggered by initiation of Phase 3 clinical trial in NSCLC by Incyte ROCKVILLE, MD, Sept. 21, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage...
MacroGenics Announces Presentation of MGD019 Phase 1 Data at the ESMO Virtual Congress 2020
September 20, 2020 09:10 ET
|
MacroGenics, Inc.
MGD019 well-tolerated with early signals of activity in advanced solid tumors not typically responsive to checkpoint inhibitionRecommended Phase 2 dose established for MSS CRC, NSCLC expansion...
MacroGenics to Participate in Upcoming Investor Conferences
September 03, 2020 07:30 ET
|
MacroGenics, Inc.
ROCKVILLE, MD, Sept. 03, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...
MacroGenics to Participate in Upcoming Investor Conferences
August 05, 2020 16:30 ET
|
MacroGenics, Inc.
ROCKVILLE, MD, Aug. 05, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...